BioRestorative Therapies (BRTX) Net Cash Flow (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Net Cash Flow came in at $923917.0 in Q4 2025, up 198.13% on a YoY basis from $309907.4 in Q4 2024, and up 197.08% quarter-over-quarter from -$951670.0 in Q3 2025.
Powered by 
Analysis
BioRestorative Therapies (BRTX) Net Cash Flow (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has reported Net Cash Flow for 16 consecutive years, with $923917.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 198.13% year-over-year to $923917.0; the trailing twelve-month figure through Dec 2025 stood at $952261.0 (up 383.0% YoY), and the FY2025 full-year result was $952261.0, up 383.0% from the prior year.
- Net Cash Flow grew to $923917.0 in Q4 2025 per BRTX's latest filing, from -$951670.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $19.9 million in Q4 2021 and bottomed at -$11.4 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$97275.1 across 5 years, with a median of -$596532.5 in 2021.
- The widest YoY moves for Net Cash Flow: up 589.87% in 2021, down 18190.53% in 2021.
- Over 5 years, Net Cash Flow stood at $19.9 million in 2021, then slumped by 124.38% to -$4.9 million in 2022, then surged by 67.29% to -$1.6 million in 2023, then soared by 40.77% to -$941554.0 in 2024, then soared by 198.13% to $923917.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $923917.0, -$951670.0, and $320329.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | -71.74 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -131.98 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -85.58 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 26.80 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 273.80 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -68.45 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 8.85 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 103.70 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 16.06 Mn |
| 10 | BioRestorative Therapies | 62,133.68 | -2.89 Mn | 17,964.00 | 923,917.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 923,917.00 |
| Sep 30, 2025 | -951,670.00 |
| Jun 30, 2025 | 320,329.00 |
| Mar 31, 2025 | 659,685.00 |
| Dec 31, 2024 | -941,554.00 |
| Sep 30, 2024 | -762,803.00 |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 272,703.00 |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | 653,223.00 |
| Jun 30, 2023 | -464,524.00 |
| Mar 31, 2023 | 159,892.00 |
| Dec 31, 2022 | -4.86 Mn |
| Sep 30, 2022 | -11.36 Mn |
| Jun 30, 2022 | -1.39 Mn |
| Mar 31, 2022 | -1.70 Mn |
| Dec 31, 2021 | 19.93 Mn |
| Sep 30, 2021 | -629,364.00 |
| Jun 30, 2021 | -741,829.00 |
| Mar 31, 2021 | -563,701.00 |